Register by February 15, 2008 and Save up to $400!

Radiographic imaging is playing a much larger role than ever before in the assessment of new drug candidates in R & D. With technology evolving so rapidly, many in clinical development are not sure which techniques are available to them, whether they can be implemented into a clinical development program and how to implement them. This conference will provide you with solutions to these issues.

Conference Coverage Includes:

• Imaging in drug/device development the big picture 

  • Patient Selection

  • Proof of principle, biologic activity

  • Optimization of dose and schedule

  • Surrogate marker for clinical outcome parameter

  • Safety assessment

• Selection and application of various imaging tools

• Challenges in the design and analysis of clinical trials using imaging endpoints

• Partnering with Imaging Service Providers

• Quality control and data management of imaging data

• Application of imaging tools in oncology, CNS, and cardiovascular clinical development programs 

• Up and coming technologies

Who Should Attend

• Directors

• Clinical Data Management

• Clinical Managers

• Clinical Operations Personnel

• Clinical Researchers

• Medical Research Scientists

• Radiologists

• Regulatory Affairs

Short Course - Imaging Tools Currently Available: 
How they Work, Questions they Answer, Study Management and Logistics

• CT scan

• MRI

• PET

The Role of Imaging in Drug/Device Development
Speaker to be announced

Setting Endpoints Using Imaging Biomarkers in Clinical Trials
Thomas J FitzGerald, M.D., Professor and Chair, Radiation Oncology, University of Massachusetts Medical School

Practical Considerations for Selection and Partnering with Imaging Service Providers
Jane Davis Golden, P.T., M.H.P., Associate Director, Medical Research, Wyeth

IT Solutions for the Management of Imaging Data
Joanna Fueyo, Ph.D., Senior Solutions Scientist, Medical Imaging Solutions, IBM Healthcare and Life Sciences

Imaging in Preclinical Cancer Research
Werner Scheurer, Ph.D., Oncology, Roche Diagnostics GmbH

Imaging Techniques for Assessing Drug Safety
Ken Faulkner, Ph.D., VP Scientific Services, Synarc

Case Study: Use of CT Imaging in the Evaluation of Hemostatic Agents
Brett Skolnick, M.D., Senior Director, Hemostasis, Novo Nordisk

Case Study: BMS-747158-02: A Novel PET Myocardial Perfusion Imaging Agent
Mahesh Mistry, Ph.D., Discovery Biology, Bristol Meyers Squibb Medical Imaging

Case Study: PET Receptor Occupancy – Accelerating Drug Development by Non-Invasive Measurement of Drug Action Early in the Development Pipeline
Robert A. Comley, Ph.D., Imaging Scientist, Clinical Molecular Imaging, GlaxoSmithKline